Coya Therapeutics, Inc.
COYA evidence brief
What we can confirm
- BioSniper Score:
- 7.7 / 10
- Market Cap:
- $102.7M
- Lead Asset:
- COYA 302 (Phase 2/Phase 3)
What it means
What to watch
Prepared research question
What matters most for COYA—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · COYA
Coya Therapeutics is a clinical-stage biotechnology company developing Treg-enhancing biologics, with its lead candidate COYA 302 in a Phase 2 ALS trial and a cash runway into the second half of 2027.
Key risk: No approved products
BioSniper Score
Based on 3 of 6 signals
Limited data coverage
Market Cap
$102.7M
Cash Runway
—
Lead Asset
COYA 302 (Phase 2/Phase 3)
Next Catalyst
—
Financial data as of Jun 30, 2026.
Tracking 2 pipeline candidates · 6 clinical trials for Coya Therapeutics, Inc..
Coya Therapeutics is a clinical-stage biotechnology company developing Treg-enhancing biologics, with its lead candidate COYA 302 in a Phase 2 ALS trial and a cash runway into the second half of 2027.
- Cash & equivalents of $43.2M as of 2026-06-30 [sec].
- Total revenue of $0.2M and net income of -$6.6M as of 2026-06-30 [sec].
- Lead candidate COYA 302 is in a Phase 2, randomized, double-blind, placebo-controlled trial (ALSTARS) for ALS [sec_mda · as of 2026-03-16].
- FDA granted Fast Track Designation for COYA 302 on May 11, 2026 [sec_mda · as of 2026-08-11].
- Projected cash runway into the second half of 2027, past the expected ALSTARS topline readout in Q1 2027 [sec · filed 2026-01-20].
What works
- Cash runway extends into H2 2027, past the projected ALSTARS topline readout in Q1 2027 [sec · filed 2026-01-20].
- COYA 302 has received FDA Fast Track Designation, which may expedite development and review [sec_mda · as of 2026-08-11].
- The company has a partnership with Dr. Reddy's, announced in January 2026 [news · published 2026-01-20].
- COYA 302 is described as a 'Pipeline in a Product' with potential for multiple indications [sec_mda · as of 2026-08-11].
What to weigh
- The company has no approved products and has not generated significant revenue from product sales [sec_mda · as of 2026-03-16].
- Net losses were $21.2 million and $14.9 million in recent periods, and the company expects to need substantial additional capital [sec_mda · as of 2026-03-16].
- COYA 302 is an investigational product not yet approved by the FDA or any other regulatory agency [sec_mda · as of 2026-08-11].
- The company's operations are entirely dependent on raising capital through equity, debt, or partnerships, with no assurance of success [sec_mda · as of 2026-03-16].
From the filings
Quoted directly from source documents.
COYA 302 Phase 2 ALSTARS trial and Fast Track Designation
“On May 11, 2026, the FDA granted Fast Track Desi”
SEC MD&A · August 11, 2026
Cash runway into H2 2027 and ALSTARS topline readout in Q1 2027
“projected cash runway into the second half of 2027, and that the Company expects a topline data readout from its current ALSTARS Phase 2”
SEC filings · January 20, 2026
Need for additional capital
“We will need to raise substantial additional capital to support our continuing operations and pursue our growth strategy.”
SEC MD&A · March 16, 2026
Risks & what to watch (3)›
Key risks
- No approved products — COYA 302 is not yet approved by the FDA or any other regulatory agency [sec_mda · as of 2026-08-11].
- Dependence on external financing — The company expects to need substantial additional capital with no assurance of obtaining it [sec_mda · as of 2026-03-16].
- Clinical trial uncertainty — The ALSTARS Phase 2 trial is ongoing and topline data is not expected until Q1 2027 [sec · filed 2026-01-20].
What to watch
- Topline data readout from the ALSTARS Phase 2 trial expected in Q1 2027 [sec · filed 2026-01-20].
- Cash runway into the second half of 2027 and any subsequent financing needs [sec · filed 2026-01-20].
- Progress of the Dr. Reddy's partnership and any additional collaborations [news · published 2026-01-20].
- Regulatory milestones related to the FDA Fast Track Designation for COYA 302 [sec_mda · as of 2026-08-11].
Sources: Catalysts · News · SEC filings · SEC MD&A · Generated September 27, 2026 · How we verify sources →
Run Coya Therapeutics, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Coya Therapeutics, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 3 of 6 signals · derived from public data
Cash runway data unavailable
D/E 0.09 · 0% dilution
Lead: Phase 2/Phase 3
2 candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Pipeline
Regulatory
Financials
Short Interest
as of May 20, 2026- % of float
- 3.7%
- Days to cover
- 5.6
- Shares short
- 825,568
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
COYA short interestGovernance
Frequently asked questions
What is the AI investment thesis for Coya Therapeutics, Inc.?
Coya Therapeutics is a clinical-stage biotechnology company developing Treg-enhancing biologics, with its lead candidate COYA 302 in a Phase 2 ALS trial and a cash runway into the second half of 2027.
What is Coya Therapeutics, Inc.'s lead drug candidate?
Coya Therapeutics, Inc.'s most advanced tracked candidate is COYA 302 (Phase 2/Phase 3) for Amyotrophic Lateral Sclerosis (ALS).
Who is the CEO of Coya Therapeutics, Inc.?
Dr. Arun Swaminathan Ph.D. is the chief executive officer of Coya Therapeutics, Inc. (COYA).
Where is Coya Therapeutics, Inc. headquartered?
Coya Therapeutics, Inc. (COYA) is headquartered in Houston, TX, United States.
What therapeutic areas does Coya Therapeutics, Inc. focus on?
Coya Therapeutics, Inc. develops therapies across Oncology, Gene Therapy, Neurology, Nephrology, Gastroenterology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.